Answers are grounded in this paper and cite their sources.
Background Systemic inflammation plays an important role in tumor progression and therapeutic resistance. Inflammation-based hematologic indices, including the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), have been investigated as potential prognostic markers. This study evaluated the associations of baseline values and early changes in these indices with treatment response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving first-line bevacizumab plus folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy. Methods We retrospectively analyzed 189 patients with confirmed mCRC who received first-line bevacizumab plus FOLFOX between March 2023 and June 2024. NLR and PLR were assessed at cycles 1 (C1) and 2 (C2), and early NLR change was calculated as ΔNLR = NLR at C2 − NLR at C1. Patients were also classified into four longitudinal NLR patterns according to baseline and early on-treatment NLR levels. Associations with objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated using logistic regression, receiver operating characteristic analysis, Kaplan–Meier estimation, and Cox regression. Results Among 189 patients, median PFS was 13.6 months, whereas median OS was not reached. Higher baseline NLR was independently associated with inferior OS (adjusted hazard ratio [HR], 1.172; 95% confidence interval [CI], 1.078–1.273; p < 0.001), whereas baseline PLR and ΔNLR were not independently associated with survival outcomes. None of the inflammatory indices was independently associated with objective response, with limited discriminatory performance (AUCs of 0.620, 0.590, and 0.491 for baseline NLR, PLR, and ΔNLR, respectively). Longitudinal NLR patterns showed significant differences in OS (p < 0.001) and ORR (p = 0.012), but not PFS (p = 0.061). The Low–Low group exhibited the highest ORR (71.6%), whereas the High–High group had a lower ORR (45.5%) and a median OS of 19.4 months. Conclusion Baseline NLR was independently associated with OS in patients with mCRC receiving first-line bevacizumab plus FOLFOX. Although early NLR change alone showed limited prognostic value, longitudinal NLR patterns were associated with differences in survival and treatment response. Serial NLR assessment may offer a simple and accessible approach to risk stratification, warranting further prospective validation.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: